Person: Adler, Nicole
Lade...
E-Mail-Adresse
Geburtsdatum
Forschungsvorhaben
Organisationseinheiten
Berufsbeschreibung
Nachname
Adler
Vorname
Nicole
Name
2 Ergebnisse
Suchergebnisse
Gerade angezeigt 1 - 2 von 2
Veröffentlichung New Test Strategy for Dung Beetles During the Authorization Process of Parasiticides(2013) Adler, Nicole; Bachmann, Jean; Römbke, JörgAccording to European legislation, an environmental risk assessment (ERA) of veterinary medicinal products (VMPs) for dung fauna is required in the authorization process, if the substance acts as a parasiticide for the treatment of pasture animals. In the past, however, the demonstration of the environmental safety of those VMPs for dung fauna was strongly hampered by the fact that no standardized tests were available. Therefore, starting with recommendations from the Society of Environmental Toxicology and Chemistry (SETAC) advisory group, dung organism toxicity test standardization (DOTTS) test systems for phase II Tier A standardized tests on the mortality of dung fly and dung beetle larvae were developed and published by the Organisation for Economic Co-operation and Development (OECD) in 2008 and 2010. If a risk is identified for dung organisms in phase II Tier A of the ERA process, further tests are required for Tier B. So far, however, no advice is given for such studies in the existing guidelines. Therefore, 4 workshops took place between 2007 and 2009 with international dung fauna experts (Aveiro-Group) to find an appropriate test strategy for dung fauna organisms beyond Tier A mortality testing. For the first time, 2 different Tier B extended laboratory test approaches for dung beetles and test strategies for scenarios beyond Tier B are described in more detail. In case the risk assessment is still not clear, further options for Tier C (i.e., field studies) or Tier D (modeling) are briefly presented. Finally, the role of uncertainty and variability of test results is discussed, including recommendations for assessment factors for the different tiers to be used when assessing the risk of VMPs on dung organisms. The approach, especially the test strategy, will help industry, consultants, and assessors appropriately assess the environmental risk assessments during the authorization procedure of parasiticides. Integr Environ Assess Manag 2013;9:524-530. © 2013 SETACVeröffentlichung Pharmaceuticals in the environment(2014) Küster, Anette; Adler, NicoleDuring the past two decades scientists, regulatory agencies and the European Commission have acknowledged pharmaceuticals to be an emerging environmental problem. In parallel, a regulatory framework for environmental risk assessment (ERA) of pharmaceutical products has been developed. Since the regulatory guidelines came into force the German Federal Agency (UBA) has been evaluating ERAs for human and veterinary pharmaceutical products before they are marketed. The results show that approximately 10% of pharmaceutical products are of note regarding their potential environmental risk. For human medicinal products, hormones, antibiotics, analgesics, antidepressants and antineoplastics indicated an environmental risk. For veterinary products, hormones, antibiotics and parasiticides were most often discussed as being environmentally relevant. These results are in good correlation with the results within the open scientific literature of prioritization approaches for pharmaceuticals in the environment. UBA results revealed that prospective approaches, such as ERA of pharmaceuticals, play an important role in minimizing problems caused by pharmaceuticals in the environment. However, the regulatory ERA framework could be improved by (i) inclusion of the environment in the risk-benefit analysis for human pharmaceuticals, (ii) improvement of risk management options, (iii) generation of data on existing pharmaceuticals, and (iv) improving the availability of ERA data. In addition, more general and integrative steps of regulation, legislation and research have been developed and are presented in this article. In order to minimize the quantity of pharmaceuticals in the environment these should aim to (i) improve the existing legislation for pharmaceuticals, (ii) prioritize pharmaceuticals in the environment and (iii) improve the availability and collection of pharmaceutical data.
Quelle: http://www.researchgate.net/